IntelGenx Technologies Corp. (IGXT)
OTCMKTS
· Delayed Price · Currency is USD
0.1670
-0.0065 (-3.75%)
At close: May 16, 2024
IntelGenx Technologies Revenue
IntelGenx Technologies had revenue of $174.00K in the quarter ending March 31, 2024, with 7.41% growth. This brings the company's revenue in the last twelve months to $1.05M, up 20.11% year-over-year. In the year 2023, IntelGenx Technologies had annual revenue of $1.04M with 9.37% growth.
Revenue (ttm)
1.05M
Revenue Growth
+20.11%
P/S Ratio
27.75
Revenue / Employee
21.02K
Employees
50
Market Cap
29.17M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.04M | 89.00K | 9.37% |
Dec 31, 2022 | 950.00K | -585.00K | -38.11% |
Dec 31, 2021 | 1.54M | -9.00K | -0.58% |
Dec 31, 2020 | 1.54M | 802.00K | 108.09% |
Dec 31, 2019 | 742.00K | -1.08M | -59.32% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
SS Innovations International | 16.04M |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 200.90M |
Northwest Biotherapeutics | 1.60M |
Silence Therapeutics | 43.26M |
American Oncology Network | 1.76B |
IntelGenx Technologies News
- 9 months ago - IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process - GlobeNewsWire
- 9 months ago - IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA' Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease - GlobeNewsWire
- 10 months ago - IntelGenx Announces Initiation of the Sale and Investment Solicitation Process - GlobeNewsWire
- 10 months ago - IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process - GlobeNewsWire
- 11 months ago - IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives - GlobeNewsWire
- 11 months ago - IntelGenx Announces Voting Results on Election of Directors - GlobeNewsWire
- 1 year ago - IntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK' Clinical Trial - GlobeNewsWire
- 1 year ago - IntelGenx Updates Status of Buprenorphine Buccal Film ANDA - GlobeNewsWire